HLS Therapeutics Inc.
HLTRF
$3.15
-$0.11-3.37%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -1.81% | -1.98% | -1.92% | -4.20% | -6.61% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -1.81% | -1.98% | -1.92% | -4.20% | -6.61% |
| Cost of Revenue | 4.48% | 7.71% | 9.63% | 9.68% | 12.67% |
| Gross Profit | -4.16% | -5.36% | -5.81% | -8.62% | -12.23% |
| SG&A Expenses | -15.00% | -18.31% | -14.14% | -11.36% | -9.23% |
| Depreciation & Amortization | -0.74% | -3.96% | -10.45% | -19.40% | -24.99% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -5.23% | -7.31% | -7.55% | -10.16% | -11.54% |
| Operating Income | 35.56% | 46.58% | 45.33% | 46.56% | 39.72% |
| Income Before Tax | 22.98% | 17.37% | 23.03% | 27.43% | 50.52% |
| Income Tax Expenses | -110.30% | -110.93% | -92.94% | -93.37% | 1,662.84% |
| Earnings from Continuing Operations | 42.78% | 36.76% | 35.92% | 37.55% | 35.41% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 42.78% | 36.76% | 35.92% | 37.55% | 35.41% |
| EBIT | 35.56% | 46.58% | 45.33% | 46.56% | 39.72% |
| EBITDA | 13.57% | 18.12% | 5.69% | -6.69% | -18.94% |
| EPS Basic | 43.12% | 37.22% | 34.91% | 36.56% | 34.14% |
| Normalized Basic EPS | 38.52% | 32.01% | 32.25% | 29.05% | 18.81% |
| EPS Diluted | 43.17% | 37.20% | 33.83% | 35.57% | 33.50% |
| Normalized Diluted EPS | 38.52% | 32.01% | 32.25% | 29.05% | 18.81% |
| Average Basic Shares Outstanding | 1.72% | 2.01% | -1.69% | -1.74% | -2.16% |
| Average Diluted Shares Outstanding | 1.72% | 2.01% | -1.69% | -1.74% | -2.16% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |